MF101, a selective estrogen receptor β modulator for the treatment of menopausal hot flushes: A phase II clinical trial

Menopause

Volumn 16, Issue 3, 2009, Pages 458-465

  Grady, Deborah ^a,b   Sawaya, George F ^a   Johnson, Karen C ^c   Koltun, William ^d   Hess, Rachel ^e   Vittinghoff, Eric ^a   Kristof, Margaret ^a   Tagliaferri, Mary ^f   Cohen, Isaac ^f   Ensrud, Kristine E ^g,h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d Medical Center for Clinical Research   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f Bionovo   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h VA MEDICAL CENTER   (United States)

Author keywords

Estrogen receptor selective estrogen; Hot flush

Indexed keywords

HERBACEOUS AGENT; MENOPAUSAL FORMULA 101; MF101; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOT FLUSH; HUMAN; HUMAN TISSUE; IDIOPATHIC PANCREATITIS; LOOSE FECES; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; OPTIMAL DRUG DOSE; PANCREATITIS; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIUM; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; METRORRHAGIA; MIDDLE AGED; PLANT EXTRACTS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 67649866374     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31818e64dd     Document Type: Article

References (20)

1. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152:463-473.
2. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86; discussion 123-133.
3. Nelson HD, Haney E, Humphrey L, et al. Management of Menopause-related Symptoms. Publication No. 05-E016-2. Rockville, MD: Agency for Healthcare Research and Quality, 2005.
4. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-313.
5. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291: 1701-1712.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
7. Grady D. Management of menopausal symptoms. N Engl J Med 2006; 355:2338-2347.
8. Cvoro A, Paruthiyil S, Jones JO, et al. Selective activation of estrogen receptor-β transcriptional pathways by an herbal extract. Endocrinology 2007;148:538-547.
9. Ware JE Jr. SF-36 health survey update. Spine 2000;25:3130-3139.
10. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-175.
11. Rosen RC, Catania JA, Ehrhardt AA, et al. The Bolger conference on PDE-5 inhibition and HIV risk: implications for health policy and prevention. J Sex Med 2006;3:960-975; discussion 973-975.
12. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-4290.
13. McCulloch CESS. Generalized, Linear, and Mixed Models. New York, NY: Wiley; 2001.
14. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes. JAMA 2004;291:1610-1620.
15. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637-645.
16. Loprinzi CL, Zahasky KM, Sloan JA, Novotny PJ, Quella SK. Tamoxifen-induced hot flashes. Clin Breast Cancer 2000;1:52-56.
17. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor β inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004;64:423-428.
18. Chakravarty D, Srinivasan R, Ghosh S, Gopalan S, Raiwanshi A, Maiumdar S. Estrogen receptor β1 and the β2/betacx isoforms in nonneoplastic endometrium and in endometrial carcinoma. Int J Gynecol Cancer 2007;4:905-913.
19. Mylonas I, Jeschke U, Shabani N, et al. Steroid receptors ERα, ERβ, PR-A and PR-B are differently expressed in normal and atrophic human endometrium. Histol Histopathol 2007;22:169-176.
20. Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 2005;67: 285-308.